|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
PEG-LPrA2 significantly reduced BC growth (untreated: 19/42; [45%] vs. treated: 8/42 [19%]; Pearson χ(2) : p = 0.008).
|
24114531 |
2014 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
The interaction of NMOF/PEG with the breast cancer cell line (MCF-7) was examined by BIO-TEM analysis and laser confocal imaging.
|
28910676 |
2017 |
|
Malignant neoplasm of breast
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The in vivo test demonstrates approximately 6-fold enhanced accumulation of TMPC in xenograft tumors with a longer retention time compared to that of the PEG-Ce6 conjugate at 24 h. Thus, trastuzumab and photosensitizer conjugation brings synergistic effects for HER2 selective targeting, where TMPC enhanced tumor tissue penetration improves tumor tissue access and responsiveness of trastuzumab in HER2 overexpressing breast cancer.
|
29578555 |
2018 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Knowing that TA can bind to CD44-receptors in breast cancer, this study was intended to validate the safety and feasibility of systemic miRNA delivery to breast cancer cells by TA-PEG-PAMAM/miRNA (polyethylene glycol - PEG), testify its tumor targeting efficiency in vitro, and observe its biodistribution when it was administered systemically to a xenograft mouse model of breast cancer.
|
26299192 |
2016 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
A recent study used the PLGA-PEG-helenalin complex, and free helenalin, to inhibit the expression of telomerase in the breast cancer cell line.
|
25435410 |
2016 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
pH multistage responsive micellar system with charge-switch and PEG layer detachment for co-delivery of paclitaxel and curcumin to synergistically eliminate breast cancer stem cells.
|
28930649 |
2017 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
The influence of glycerides ± PEG on the cytotoxicity of SV was evaluated on MCF-7 breast cancer cells, in addition to the cellular uptake of fluorescent blank NLCs.
|
28276784 |
2017 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
In vitro studies showed that GNRs-MPH<sup>-ALA/DOX</sup>-PEG could efficiently enter human breast cancer MCF-7 cells and release DOX and ALA into cytoplasm.
|
30336271 |
2018 |
|
Malignant neoplasm of breast
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Expression of glycodelin in MCF-7 breast cancer cells induces differentiation into organized acinar epithelium.
|
9426393 |
1997 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
It was obvious that MDM2 can serve as a novel therapeutic target by an effective carrier system of DSPE-PEG-Amine-functionalized SWNTs, which would be very advanced and significant to therapy of breast cancer further.
|
22397761 |
2012 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
The fusion efficiency of either breast cancer cell line with M2 macrophages ranged from 1.81 to 6.47% in the presence of PEG, and no significant difference was observed between the breast cancer cell lines used (p>0.05).
|
22848668 |
2012 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, PEG-G3-PEITC is a promising drug delivery system for PTX in the treatment of breast cancer.
|
29572777 |
2018 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Preparation of anastrozole loaded PEG-PLA nanoparticles: evaluation of apoptotic response of breast cancer cell lines.
|
29343958 |
2018 |
|
Malignant neoplasm of breast
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Glycodelin and survivin transcriptional activity are associated with adverse clinicopathologic and molecular characteristics of node-positive primary breast cancer but do not predict patient outcome.
|
16823513 |
2006 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Synthesis and Characterization of PLGA-PEG Thymoquinone Nanoparticles and Its Cytotoxicity Effects in Tamoxifen-Resistant Breast Cancer Cells.
|
30560443 |
2018 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
PEG-functionalized zinc oxide nanoparticles induce apoptosis in breast cancer cells through reactive oxygen species-dependent impairment of DNA damage repair enzyme NEIL2.
|
27940348 |
2017 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Preparation and Evaluation of Chrysin Encapsulated in PLGA- PEG Nanoparticles in the T47-D Breast Cancer Cell Line.
|
25987033 |
2015 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
EGFR-targeting PLGA-PEG nanoparticles as a curcumin delivery system for breast cancer therapy.
|
29052674 |
2017 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our results suggest that glycodelin acts as a tumor suppressor in breast cancer.
|
18720404 |
2008 |
|
Malignant neoplasm of breast
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Moreover, the patients with glycodelin-positive tumours had an increased risk for distant metastases (P = 0.001) and in multivariate analysis glycodelin expression was an independent predictor of metastasis (hazard ratio (HR) = 2.22, 95% confidence interval (95% CI) = 1.22-4.03, P = 0.009) in familial non-BRCA1/2 breast cancer.
|
20676758 |
2011 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
One aim of this research was assess the FA-mediated cell viability assay of PEG-PAMAM G4-FA-5FU-<sup>99m</sup>Tc and in vitro uptake of PEG-PAMAM G4-FA-<sup>99m</sup>Tc as the novel nano-complex determined on C2Cl2 (normal cell) and MCF-7 (breast cancer cell) cell lines.Other main goals were studied.
|
28800462 |
2017 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Co-delivery of docetaxel and verapamil by reduction-sensitive PEG-PLGA-SS-DTX conjugate micelles to reverse the multi-drug resistance of breast cancer.
|
27988472 |
2017 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
On the basis of these results, we speculate that glycodelin could be used as a prognostic marker for breast cancer.
|
15706409 |
2005 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Liposomal doxorubicin loaded PLGA-PEG-PLGA based thermogel for sustained local drug delivery for the treatment of breast cancer.
|
30686051 |
2019 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
CTD_human |
Association between glycodelin and aryl hydrocarbon receptor in Iranian breast cancer patients: impact of environmental endocrine disrupting chemicals.
|
22296396 |
2011 |